S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
LON:IMM

ImmuPharma Share Forecast, Price & News

GBX 5.43
+0.43 (+8.60%)
(As of 12/3/2021 04:30 PM ET)
Add
Compare
Today's Range
4.87
5.61
50-Day Range
5
7.96
52-Week Range
4.86
14.05
Volume
1.06 million shs
Average Volume
925,574 shs
Market Capitalization
£13.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive IMM News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmuPharma and its competitors with MarketBeat's FREE daily newsletter.


ImmuPharma logo

About ImmuPharma

ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity, metabolism, anti-infectives, and cancer. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidate includes IPP-204106, a peptide to modulate angiogenesis with application in cancer and ophthalmology; and BioGlucagon a therapy for low sugar events in diabetes. ImmuPharma plc has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
18
Year Founded
N/A

Sales & Book Value

Annual Sales
£87.99 thousand
Cash Flow
GBX 1.42 per share
Book Value
GBX 2.10 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
£13.59 million
Optionable
Not Optionable

Company Calendar

Last Earnings
9/30/2020
Today
12/05/2021

MarketRank

Overall MarketRank

1.00 out of 5 stars

Analyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












ImmuPharma (LON:IMM) Frequently Asked Questions

How has ImmuPharma's stock price been impacted by Coronavirus?

ImmuPharma's stock was trading at GBX 10.76 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, IMM shares have decreased by 49.5% and is now trading at GBX 5.43.
View which stocks have been most impacted by COVID-19
.

How were ImmuPharma's earnings last quarter?

ImmuPharma plc (LON:IMM) released its quarterly earnings data on Wednesday, September, 30th. The company reported ($1.69) EPS for the quarter.
View ImmuPharma's earnings history
.

Who are ImmuPharma's key executives?

ImmuPharma's management team includes the following people:
  • Mr. Dimitri F. Dimitriou, Co-Founder, CEO & Director (Age 59, Pay $320.3k)
  • Dr. D. Robert Henri Zimmer, Co-Founder, Pres, Chief Scientific Officer & Director (Age 73, Pay $356.39k)
  • Mr. Peter Hein, Interim Chief Financial Officer (Age 64)
  • Dr. Timothy Gary Franklin M.B.A., Ph.D., Chief Operating Officer
  • Ms. Lisa Baderoon, Head of Investor Relations
  • Dr. Jean-Marie Geiger PharmD, MD, Head of Clinical Devel.
  • Ms. Ewa Flynn M.A., Financial Controller & Company Sec.

What other stocks do shareholders of ImmuPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ImmuPharma investors own include Castleton Technology (CTP), MOTIF BIO PLC/S (MTFB), Aminex (AEX), Legendary Investments (LEG), Richland Resources Ltd (RLD.L) (RLD), Sound Energy (SOU), Thor Mining (THR), Acacia Mining (ACA), ALU (ALU) and (DARA) (DARA).

What is ImmuPharma's stock symbol?

ImmuPharma trades on the London Stock Exchange (LON) under the ticker symbol "IMM."

How do I buy shares of ImmuPharma?

Shares of IMM and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is ImmuPharma's stock price today?

One share of IMM stock can currently be purchased for approximately GBX 5.43.

How much money does ImmuPharma make?

ImmuPharma has a market capitalization of £13.59 million and generates £87.99 thousand in revenue each year.

How many employees does ImmuPharma have?

ImmuPharma employs 18 workers across the globe.

What is ImmuPharma's official website?

The official website for ImmuPharma is www.immupharma.org.

Where are ImmuPharma's headquarters?

ImmuPharma is headquartered at 50 Broadway, LONDON, SW1H 0BL, United Kingdom.

How can I contact ImmuPharma?

ImmuPharma's mailing address is 50 Broadway, LONDON, SW1H 0BL, United Kingdom. The company can be reached via phone at +44-20-71524080.


This page was last updated on 12/5/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.